BRAF and neoplasm: No significant correlation with disease specific survival was found with the presence of BRAF mutations or RAS mutations alone or in coexistence with TPM. When the analysis of tumor-related death was approached in the 20 cases without DMs, TERT amplification also emerged as a better predictor of reduced survival than TPM (Log-rank P < 0.0001 and Log-rank P = 0.0140, respectively) (“Online resource – Figure-2”).